Figure 1.
ISCL criteria and CD158k and PD-1 expressions on CD4+CD26− cells. (A) The CD4/CD8 ratio in patients without CTCL (non-CTCL; n = 156), with another type of CTCL (CTCL; n = 18), with MF (n = 39) or with SS (n = 18). (B) Percentage of CD4+CD26− lymphocytes (n = 156, n = 18, n = 39, n = 18, respectively). (C) Percentage of CD4+CD7− lymphocytes (n = 155, n = 18, n = 39, n = 18, respectively). (D) Percentage of CD158k+ SS-like cells (n = 149, n = 18, n = 39, n = 18, respectively). (E) Percentage of PD-1+ SS-like cells (n = 122, n = 18, n = 36, n = 18, respectively). (F) Absolute values of CD4+CD26− lymphocytes (n = 156, n = 18, n = 39, n = 18, respectively). (G) Absolute values of CD4+CD7− lymphocytes (n = 155, n = 18, n = 39, n = 18, respectively). (H) Absolute values of CD158k+ SS-like cells (n = 149, n = 18, n = 39, n = 18, respectively). (I) Absolute values of PD-1+ SS-like cells (n = 122, n = 18, n = 36, n = 18, respectively). ns, not significant.

ISCL criteria and CD158k and PD-1 expressions on CD4+CD26− cells. (A) The CD4/CD8 ratio in patients without CTCL (non-CTCL; n = 156), with another type of CTCL (CTCL; n = 18), with MF (n = 39) or with SS (n = 18). (B) Percentage of CD4+CD26− lymphocytes (n = 156, n = 18, n = 39, n = 18, respectively). (C) Percentage of CD4+CD7− lymphocytes (n = 155, n = 18, n = 39, n = 18, respectively). (D) Percentage of CD158k+ SS-like cells (n = 149, n = 18, n = 39, n = 18, respectively). (E) Percentage of PD-1+ SS-like cells (n = 122, n = 18, n = 36, n = 18, respectively). (F) Absolute values of CD4+CD26− lymphocytes (n = 156, n = 18, n = 39, n = 18, respectively). (G) Absolute values of CD4+CD7− lymphocytes (n = 155, n = 18, n = 39, n = 18, respectively). (H) Absolute values of CD158k+ SS-like cells (n = 149, n = 18, n = 39, n = 18, respectively). (I) Absolute values of PD-1+ SS-like cells (n = 122, n = 18, n = 36, n = 18, respectively). ns, not significant.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal